pISSN 1009-3419 **日**国肺癌杂志。[ISSN 1009-3419 (ISSN 1999-6187 (N) 12-1395/R

首页 | 关于我们 | 登录 | 注册 | 搜索 | 最新一期 | 过刊浏览 | 公告 | 稿约 | 在线投稿 | Online submission ARTICLE TOOLS Endnote参考文献模板 提前在线出版 i 索引源数据 ■ 首页 > 卷 12, 编号 8 (2009) > DUAN 🔯 如何引证项目 查找参考文献 宙杳政策 The Clinical Applications of Combined HBV Approach to Chemotherapy Email this article for Non-small Cell Lung Cancer while Adoption of Antivirus Therapy (Login required) Lincan DUAN, Gaofeng LI, Yong ZHANG, Lianhuan YE RELATED ITEMS 摘要 Related studies Background and objective Lung cancer has become the most serious malignant tumor Databases threating the human beings' health and life, and chemotherapy postponing or suspending Web search contributes to one of the prognostic causes. In this research, we try to explore the 📑 Show all importance of combined HBV approach to chemotherapy for non-small cell lung cancer while adoption of antivirus therapy. Methods Select 60 cases of patients suffering from combined HBV ?A non-small cell lung cancer, who were divided into two groups, the experimental ABOUT THE group and control group. For the experimental group, a NP-approach chemotherapy was AUTHORS adopted along with addition of Lamivudine (NP+Lam group), while for the control group, only NP-approach was applied (NP group), in order to compare whether there would be any Lincan DUAN statistical difference between the two groups in terms of damage to the functions of liver and immune system as well as reactivation of HBV. Results The blood serum of the patients from both of the two groups rises, with the NP group being prominently higher than the NP+Lam group on an average (P<0.05). Upon completion of the chemotherapy, the Gaofeng LI percentage of CD3+/CD4+ and CD4+/ CD8+ decreases. As the percentage of CD8+ increases, the differences in these items turn out to be marked (P<0.05). The reactivation of HBV and postponing or suspending of the chemotherapy are also find prominently different Yong ZHANG (P<0.05). Conclusion It is necessary to use antiviral therapy while the patents with combined non-small cell lung cancer receive therapy. Lianhuan YE 全文: PDF HTML Get Permission ADD THIS 🛛 📲 🗐 🍂 🚽 十编 Qinghua Zhou YoflOX 肿病防治研究 Pioneer Bioscience

å

PBPC

Thorac Dis

Publishing Company

www.thePBPC.org